References


4. European Society for Medical Oncology. EMA Recommends Granting a Marketing Authorisation for Pegylated Liposomal Formulation of Irinotecan for Metastatic Pancreatic Adenocarcinoma. It is intended in combination with 5-FU and LV in patients who have progressed following gemcitabine based therapy. July 2016.


